BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

H1N1 VLP influenza vaccine: Final Phase II data

Novavax previously reported preliminary data from the first stage of the trial showing that single doses of 15 and 45 µg of the vaccine met seroconversion and seroprotection criteria recommended by U.S. and European regulatory authorities at 14 days post-dose (see BioCentury, Dec. 7, 2009 & March 29, 2010).

Novavax Inc....

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >